GeoVax Labs Inc. (NASDAQ:GOVX) Short Interest Down 90.0% in January

GeoVax Labs Inc. (NASDAQ:GOVX) saw a significant decrease in short interest in the month of January. As of January 15th, there was short interest totaling 151,504 shares, a decrease of 90.0% from the December 31st total of 1,514,630 shares. Currently, 12.7% of the company’s stock are short sold. Based on an average daily trading volume, of 211,349 shares, the short-interest ratio is currently 0.7 days. Based on an average daily trading volume, of 211,349 shares, the short-interest ratio is currently 0.7 days. Currently, 12.7% of the company’s stock are short sold.

Hedge Funds Weigh In On GeoVax Labs

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GOVX. Jane Street Group LLC acquired a new stake in GeoVax Labs during the 1st quarter worth about $27,000. Sabby Management LLC purchased a new position in shares of GeoVax Labs in the third quarter worth about $313,000. Armistice Capital LLC acquired a new stake in shares of GeoVax Labs during the third quarter worth about $253,000. Finally, Hudson Bay Capital Management LP purchased a new stake in GeoVax Labs in the third quarter valued at approximately $47,000. Hedge funds and other institutional investors own 6.09% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. D. Boral Capital reaffirmed a “buy” rating on shares of GeoVax Labs in a research report on Wednesday, January 21st. Wall Street Zen cut shares of GeoVax Labs to a “strong sell” rating in a report on Saturday, January 17th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of GeoVax Labs in a research report on Thursday, January 22nd. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $187.50.

GeoVax Labs Stock Performance

NASDAQ GOVX remained flat at $2.84 during trading on Thursday. The company’s stock had a trading volume of 69,557 shares, compared to its average volume of 214,182. GeoVax Labs has a fifty-two week low of $2.61 and a fifty-two week high of $51.75. The company has a market capitalization of $3.41 million, a P/E ratio of -0.08 and a beta of 3.67. The firm’s fifty day moving average is $6.12 and its 200 day moving average is $12.72.

GeoVax Labs (NASDAQ:GOVX) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($7.75) EPS for the quarter, missing the consensus estimate of ($6.00) by ($1.75). GeoVax Labs had a negative net margin of 403.88% and a negative return on equity of 489.67%. On average, research analysts forecast that GeoVax Labs will post -4.49 earnings per share for the current fiscal year.

About GeoVax Labs

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.